EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Oncolytic virus and tumor-associated macrophage interactions in cancer immunotherapy

Marc Lecoultre, Paul R Walker, Aya El Helali

Clinical and Experimental Medicine · 28.08.2024 · 24 (1)

DOI: 10.1007/s10238-024-01443-8 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Experimental Medicine, online erschienen am 28.08.2024. Verfasst von Marc Lecoultre und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, Hong Kong University, Hong Kong, China. Hauptthemen laut MEDLINE: Neoplasms, Oncolytic Viruses, Immunotherapy, Oncolytic Virotherapy. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 142 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oncolytic viruses (OV) are a promising strategy in cancer immunotherapy. Their capacity to promote anti-tumoral immunity locally raises hope that cancers unresponsive to current immunotherapy approaches could be tackled more efficiently. In this context, tumor-associated macrophages (TAM) must be considered because of their pivotal role in cancer immunity. Even though TAM tend to inhibit anti-tumoral responses, their ability to secrete pro-inflammatory cytokines and phagocytose cancer cells can be harnessed to promote therapeutic cancer immunity. OVs have the potential to promote TAM pro-inflammatory functions that favor anti-tumoral immunity. But in parallel, TAM pro-inflammatory functions induce OV clearance in the tumor, thereby limiting OV efficacy and highlighting that the interaction between OV and TAM is a double edge sword. Moreover, engineered OVs were recently developed to modulate specific TAM functions such as phagocytic activity. The potential of circulating monocytes to deliver OV into the tumor after intravenous administration is also emerging. In this review, we will present the interaction between OV and TAM, the potential of engineered OV to modulate specific TAM functions, and the promising role of circulating monocytes in OV delivery to the tumor.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsOncolytic VirusesImmunotherapyOncolytic VirotherapyTumor-Associated MacrophagesHumansAnimals

Stichwörter der Autor:innen

Cancer immunotherapyOncolytic virusesPhagocytosisTumor-associated macrophages

Autor:innen und Institutionen

  • Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, Hong Kong University, Hong Kong, China.
  • Division of General Internal Medicine, Geneva University Hospital, Geneva, Switzerland.
  • Faculty of Medicine, University of Geneva, Geneva, Switzerland.
  • Immunobiology of Brain Tumours Laboratory, Center for Translational Research in Onco-Hematology, University of Geneva, Geneva, Switzerland.
  • Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, Hong Kong University, Hong Kong, China. ahelali@hku.hk.

Zitieren

APA

Lecoultre, M., Walker, P. R., & El Helali, A. (2024). Oncolytic virus and tumor-associated macrophage interactions in cancer immunotherapy. Clinical and Experimental Medicine, 24(1). https://doi.org/10.1007/s10238-024-01443-8

Vancouver

Lecoultre M, Walker PR, El Helali A. Oncolytic virus and tumor-associated macrophage interactions in cancer immunotherapy. Clinical and Experimental Medicine. 2024;24(1). doi:10.1007/s10238-024-01443-8

BibTeX
@article{Lecoultre2024,
  author = {Lecoultre, Marc and Walker, Paul R and El Helali, Aya},
  title = {Oncolytic virus and tumor-associated macrophage interactions in cancer immunotherapy},
  journal = {Clinical and Experimental Medicine},
  year = {2024},
  volume = {24},
  number = {1},
  doi = {10.1007/s10238-024-01443-8}
}
Kostenlos starten →